Close Menu

NEW YORK (360Dx) – The US interferon-gamma release assay (IGRA) tuberculosis testing market has been largely dominated by one player, but Quest Diagnostics' acquisition of the US operations of a smaller contender has potential to increase competition in the rapidly growing market, some experts say.

The leading IGRA tuberculosis test, Qiagen's QuantiFERON-TB had global sales of $185 million in 2017, about half of which was made up of US sales, according to a spokesman.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.